[go: up one dir, main page]

EP0386023A1 - Preparation de nifedipine a liberation soutenue - Google Patents

Preparation de nifedipine a liberation soutenue

Info

Publication number
EP0386023A1
EP0386023A1 EP19880908289 EP88908289A EP0386023A1 EP 0386023 A1 EP0386023 A1 EP 0386023A1 EP 19880908289 EP19880908289 EP 19880908289 EP 88908289 A EP88908289 A EP 88908289A EP 0386023 A1 EP0386023 A1 EP 0386023A1
Authority
EP
European Patent Office
Prior art keywords
parts
formulation
nifedipine
coating
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19880908289
Other languages
German (de)
English (en)
Inventor
Brian William Barry
Bryan Arthur Mulley
Peter York
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
APS Research Ltd
Original Assignee
APS Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by APS Research Ltd filed Critical APS Research Ltd
Publication of EP0386023A1 publication Critical patent/EP0386023A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

  • This invention relates to a sustained-release formulation containing nifedipine and, most preferably, to such a formulation which will provide sustained- release of the nifedipine over a period of about twelve hours.
  • a method for preparing the sustained-release formulation is also provided.
  • a pharmaceutical which is formulated to allow the active substance or ingredient to act as quickly as possible.
  • a formulation may comprise an injectable solution or a readily dissolvable tablet or capsule. This type of formulation is useful, for instance, for treating acute pain, such as headaches, or pain associated with sudden trauma, such as an accident.
  • a pharmaceutical in such a way as to sustain its action over an extended period of time.
  • This type of administration is useful, for example, for treating chronic pain, such as that associated with rheumatic or arthritic conditions,or for the treatment of a chronic cardiovascular condition. It can be achieved by repeated administration of an immediate-release tablet or capsule at frequent intervals, for instance every four hours. However, this is generally inconvenient, especially during the night, when it is often necessary to awaken a patient to administer the tablet or capsule.
  • Nifedipine is the generic name for 4-(2'- nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1 ,4- dihydropyridine. It is a vasodilator known to be useful for the treatment of hypertension and angina pectoris. Nifedipine is practically insoluble in water and has proved difficult to formulate effectively for oral administration.
  • British Patent No. 1,173,862 relates to nifedipine itself and describes preparations thereof, optionally in admixture with an inert liquid or solid diluent or carrier, in the form of tablets and pills. These preparations have the disadvantage of a very slow and unpredictable rate of absorption from the gastrointestinal tract.
  • 3,784,684 describes oral- release capsules which are prepared by dissolving nifedipine using a solubilising agent and enclosing the solution in a capsule.
  • the capsules provide a very rapid release of the nifedipine in a form which is readily absorbable by the body.
  • liquid preparations in capsules are much more inconvenient to produce than solid preparations.
  • a large amount of the solubilising agent is required and so the unit doses, and thus the capsules containing them, are inevitably large. This is obviously a disadvantage with preparations intended for oral administration.
  • European Patent Application No. 0001247 relates to pharmaceutical preparations for oral administration which comprise either a solution of nifedipine in polyethylene glycol or a non-crystalline dispersion of nifedipine in polyvinylpyrrolidone. These preparations are said to be stable and to present nifedipine in a form which is easily and rapidly absorbable by the body.
  • British Patent No. 1,579,818 describes various solid pharmaceutical preparations containing nifedipine. These include preparations which comprise a mixture of nifedipine and one or more of methyl cellulose, hydroxypropyl cellulose and hydroxypropylmethyl cellulose, optionally together with other components.
  • the preparations are produced by a method which involves dissolving the ingredients in an organic solvent, which is then extracted leaving a solid composition or a powdery solid composition.
  • the resulting preparations show a rapid release of the nifedipine and are said to show the same high bioavailability within the body as the previously mentioned liquid preparations. There is no teaching or suggestion that the preparations could be formulated with a coating for achieving sustained-release properties.
  • a sustained-release formulation containing nifedipine is currently marketed in the United Kingdom under the name Adalat Retard (a registered, trade mark).
  • this formulation does not provide as good a sustained-release as is desirable.
  • the present invention is based on the discovery of such an improved sustained-release formulation.
  • a sustained-release nifedipine formulation comprising sufficient granules to provide a predetermined dose or number of doses of nifedipine, each of said granules having a diameter of between 0.5 and 2.5 mm and comprising: a) a core comprising 100 parts of nifedipine and from 50 to 800 parts of hydroxypropylmethyl cellulose; and b) a coating covering substantially the whole surface of the core and comprising 100 parts of a water insoluble but water swellable acrylic polymer and from 20 to 70 parts of a water soluble hydroxylated cellulose derivative, the weight of the coating being from 2 to 20% of the weight of the core.
  • the invention further provides a method for preparing a sustained-release formulation and which comprises: i) mixing nifedipine with hydroxypropylmethyl cellulose; ii) forming the mixture into core particles comprising 100 parts of nifedipine and from 50 to 800 parts of hydroxypropylmethyl cellulose; iii) forming a solution comprising 100 parts of a water insoluble but water swellable acrylic polymer and from 20 to 70 parts of a water soluble hydroxylated cellulose derivative; and iv) coating the said core particles with the said solution to form granules having a diameter of between 0.5 and 2.5 mm.
  • each of the granules will have a diameter of between 0.5 and 2.0 mm, preferably between 0.7 and 1.2 mm.
  • the core most preferably contains from 60 to 400 parts of hydroxypropylmethyl cellulose, more particularly from 80 to 150 parts.
  • the weight of the coating will usually be from 2 to 25% of the weight of the core.
  • the granule diameter is preferably between 1.5 and 2.0 mm
  • the coating preferably contains 20 to 70 parts of the water soluble hydroxylated cellulose derivative
  • the weight of the coating is from approximately 5 to 25% of the weight of the core.
  • the granule diameter is between 0.7 and 1.2 mm
  • the coating preferably contains 20 to 70 parts of the water soluble hydroxylated cellulose derivative
  • the weight of the coating is preferably between 5 and 15% of the weight of the core.
  • the core also preferably contains a bulking agent such as microcrystalline cellulose.
  • a bulking agent such as microcrystalline cellulose.
  • microcrystalline cellulose This is a well known form of cellulose which is partially depolymerised.
  • a particularly suitable microcrystalline cellulose is sold under the name Avicel (a registered trade mark).
  • Avicel a registered trade mark
  • other conventional bulking agents may also be used, as will be readily apparent to those skilled in the art.
  • the core may also contain a diluent, such as lactose.
  • a capillary-active agent such as sodium carboxymethylcellulose, which is sold under the name Ac-Di-Sol (a registered trade mark), may additionally be included. These components are used in conventional amounts.
  • the formulation of this invention may also contain colouring agents, sweetening agents and flavouring agents.
  • the coating preferably comprises about 30 parts of the hydroxylated cellulose derivative. If too much is present, the coating may become too sticky and the rate of release may become too high. If too little is present, the rate of release may be too low.
  • a particularly suitable hydroxylated cellulose derivative is hydroxypropylmethyl cellulose having a degree of substitution of 28 to 30% of methoxy groups and 7 to 12% of hydroxy groups. However, other equivalent materials such as hydroxypropyl, hydroxyethyl or hydroxymethyl celluloses can be used.
  • the acrylic polymer component of the coating is preferably neutral and may comprise a homopolymer or a copoly er, for instance of acrylic acid esters or methacrylic acid esters.
  • the acrylic polymer is provided as an aqueous dispersion.
  • a particularly suitable acrylic polymer is sold under the name Eudragit (a registered trade mark), which comprises a copolymer of acrylic and methacrylic acid esters and which is usually supplied as an aqueous dispersion containing approximately 30% solids.
  • Eudragit a registered trade mark
  • the nifedipine is micronised (to increase its surface area and thereby improve dissolution) and then blended with the hydroxypropylmethyl cellulose and any other constituents of the core, such as a bulking agent, a diluent and a capillary-active agent.
  • the nifedipine and the hydroxypropylmethyl cellulose may be mixed and then micronised, prior to blending with the other constituents.
  • the blending is conveniently performed by mixing the components together with some water to produce a slightly cohesive product. This is then extruded, chopped into suitable lengths, spheronised and dried to form the core particles of the formulation. The particles may then be sieved.
  • the coating is prepared by forming a solution of the hydroxylated cellulose derivative and mixing it with a dispersion of the acrylic polymer.
  • the aqueous mixture is then used to coat the dried core particles, and the coated particles are subsequently dried to produce the granules.
  • the coated granules are then sieved to ensure that they are in the correct size range.
  • the resulting granules may be supplied loose with a means for dispensing a measured amount of granules, for instance to be sprinkled on food.
  • the granules may be provided in sachets containing measured amounts. More preferably, however, the granules are placed in measured amounts in readily soluble capsules.
  • the capsule may be any of those already known in the art, and may, for instance, comprise a thin gelatin skin.
  • the capsule contains sufficient granules to provide a dose of 10, 20 or 40 mg of nifedipine.
  • the granules may, if desired, be formed into tablets using conventional tabletting machinery, although it should be recognised that normal tabletting processes would be likely to damage at least some of the coated granules.
  • sustained-release nifedipine formulation which shows effective sustained-release over any desired period and, in particular, over a twelve hour period. While not wishing to be limited by any mechanism, the inventors believe that the sustained-release properties shown by the formulation are achieved as follows. Upon being administered orally, the contents of the core of each granule is thought to dissolve quickly. It is the polymeric coating around the core which limits the subsequent release of the components of the core and hence produces the controlled sustained-release shown by the formulation.
  • Figure 1 shows the comparative in vitro dissolution profiles of a previously known formulation (Adalat Retard) and the formulation of the present invention (Apsipine 30/5).
  • Core - Micronised nifedipine and the hydroxypropylmethyl cellulose, Avicel, lactose and Ac- Di-Sol were mixed together by doubling up in a dry blender. Water was added in portions until a slightly cohesive product was formed. The cohesive product was passed through an extruder and the extruded material was chopped to produce slugs having a diameter of about 1mm and a length- of 2 to 3 mm. The slugs were spheronised by passage through a spheroniser, and the particles thus formed were dried to constant weight at 60 C. The dried particles were sieved to separate those having diameters between 0.7 and 1.5 mm.
  • the sieved core particles were rotated in a small coating pan and the coating mixture was added in portions to the pan until the weight of solids in the added coating mixture was 5% of the weight of the core particles. After each portionwise addition of coating mixture, air was blown into the pan to assist in water removal. At the end of the addition of the coating mixture, the coated core particles were dried to constant weight and sieved to produce granules having a size between 0.8 and 1.2 mm.
  • Hard gelatin capsules were each filled with the granules, to produce a total dose of 20 mg of nifedipine per capsule. In vitro experiments were then carried out to determine the release properties of this formulation in comparison to Adalat Retard.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Préparation de nifédipine (4-(2'-nitrophényle)-2, 6-diméthyle-3,5-dicarbométhoxy-1,4-dihydropyridine) à libération soutenue comportant suffisamment de granules pour fournir une dose ou un nombre de doses prédéterminé de nifédipine, chacun desdits granules ayant un diamètre compris entre 0,5 et 2,5 mm, comportant: (a) un noyau comprenant 100 parties de nifédipine et 50 à 800 parties de cellulose d'hydroxypropylméthyle; et (b) un enrobage recouvrant sensiblement toute la surface du noyau et comportant 100 parties d'un polymère acrylique insoluble mais gonflant dans l'eau, ainsi que 20 à 70 parties d'un dérivé de cellulose hydroxylé soluble dans l'eau, le poids de l'enrobage représentant 2 à 25 % du poids du noyau. Un procédé de préparation de ce composé est également décrit.
EP19880908289 1987-09-22 1988-09-22 Preparation de nifedipine a liberation soutenue Ceased EP0386023A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878722306A GB8722306D0 (en) 1987-09-22 1987-09-22 Sustained-release formulation
GB8722306 1987-09-22

Publications (1)

Publication Number Publication Date
EP0386023A1 true EP0386023A1 (fr) 1990-09-12

Family

ID=10624201

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19880908289 Ceased EP0386023A1 (fr) 1987-09-22 1988-09-22 Preparation de nifedipine a liberation soutenue

Country Status (4)

Country Link
EP (1) EP0386023A1 (fr)
JP (1) JPH03500288A (fr)
GB (1) GB8722306D0 (fr)
WO (1) WO1989002738A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001446A1 (fr) * 1990-07-20 1992-02-06 Aps Research Limited Formulations a liberation entretenue
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
ATE135214T1 (de) * 1992-02-17 1996-03-15 Siegfried Ag Pharma Darreichungsformen mit verlaengerter wirkstoffreigabe
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
WO1994005262A1 (fr) * 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Composition sous forme de matrice a liberation prolongee
IT1255968B (it) * 1992-11-27 1995-11-17 Composizioni farmaceutiche contenenti acido ursodesossicolico
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
IL123505A (en) 1996-07-08 2004-12-15 Penwest Pharmaceuticals Compan Sustained release matrix for high-dose insoluble drugs
IN186245B (fr) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
WO2002072064A2 (fr) * 2001-03-09 2002-09-19 Dow Global Technologies Inc. Composition granulaire
JP4331930B2 (ja) * 2001-10-17 2009-09-16 武田薬品工業株式会社 酸に不安定な薬物の高含量顆粒
TW200533391A (en) * 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
PH18946A (en) * 1983-04-21 1985-11-14 Elan Corp Plc Controlled absorption pharmaceutical composition
IT1178511B (it) * 1984-09-14 1987-09-09 Pharmatec Spa Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
GB8618811D0 (en) * 1986-08-01 1986-09-10 Approved Prescription Services Sustained release ibuprofen formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8902738A1 *

Also Published As

Publication number Publication date
GB8722306D0 (en) 1987-10-28
WO1989002738A1 (fr) 1989-04-06
JPH03500288A (ja) 1991-01-24

Similar Documents

Publication Publication Date Title
US5051263A (en) Controlled-release formulations
EP0255404B1 (fr) Préparation d'ibuprofen à libération prolongée
RU2163803C2 (ru) Фармацевтические композиции, содержащие дарифенацин
EP1562573B1 (fr) Granules pharmaceutiques contenant de la tamsulosine et procede permettant la preparation de ces granules
US5525354A (en) Pharmaceutical preparation and process for its manufacture
EP0580862A1 (fr) Preparation solide rapidement soluble
EP0142561A1 (fr) Preparation a base de nifedipine a action prolongee
EP0386023A1 (fr) Preparation de nifedipine a liberation soutenue
JP2003518483A (ja) 不良溶解性の薬物に対する改良された医薬組成物
EP0221732A2 (fr) Comprimés à effet retardé
EP0514967A1 (fr) Compositions à base de perles enrobées avec médicaments à faible solubilité
EP0386967A3 (fr) Matériau d'enrobage contrôlant la libération d'un médicament pour des formulations à activité prolongée
NZ232030A (en) Sustained release pharmaceutical pellet composition; theophylline compound core, coated to allow faster release rate in intestine
EP1154762B1 (fr) Compositions de capsules pharmaceutiques contenant de la loratadine et de la pseudoephedrine
CA2216277C (fr) Compositions pharmaceutiques a liberation controlee, administrees par voie orale, contenant de la nifedipine comme principe actif
JP3110794B2 (ja) １，４−ジヒドロピリジン誘導体を含有する製剤
US5445830A (en) Highly absorbable pharmaceutical composition
EP0297866A2 (fr) Agents thérapeutiques
EP0410422A2 (fr) Composition pharmaceutique hautement absorbable
EP0377439B1 (fr) Aspirine à faible dose et à libération contrôlée
US20050106253A1 (en) Pharmaceutical pellets comprising tamsulosin
EP0908177B1 (fr) Procédé pour former des compositions pharmaceutiques de bromazépam sous forme de granules ou pilules sphériques à action controlée et soutenue et compositions pharmaceutiques obtenues par ce procédé
AU703866C (en) Pharmaceutical formulations containing darifenacin
MXPA01002821A (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19910522

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19911114